Love the episode? Send us a text!

Today, we had the pleasure of having Melanie Sisk on the show to demystify the complex world of emerging endocrine therapies, often referred to as the "alphabet soup" of treatments. Melanie provided clarity on the different classes of drugs and how they interact with tumors, particularly focusing on those that target estrogen receptors.

We discussed:

• SERMs (Selective Estrogen Receptor Modulators): These drugs, like tamoxifen, block the growth of cancer cells by competing with estrogen receptors.
• SERDs (Selective Estrogen Receptor Down Regulators/Degraders): Drugs like Fluvestrant work by degrading estrogen receptors.
• SERANs (Complete Estrogen Receptor Antagonists): These block both pathways of estrogen, offering a complete blockade.
• PROTACs: A newer class that targets specific proteins, such as the estrogen receptor, to inhibit cancer growth.

+++++++++++++++++++++
Attend a free virtual SurvivingBreastCancer.org event:
https://www.survivingbreastcancer.org/events

Follow us on Instagram
Laura and Will: https://www.instagram.com/laura_and_will/
SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/
Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/

About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.

Support the show

Latest News:

• Become a Breast Cancer Conversations+ Member! Sign Up Now.
• Join our Mailing List - New content drops every Monday!